Literature DB >> 17891553

Formulation and characterization of injectable poly(DL-lactide-co-glycolide) implants loaded with N-acetylcysteine, a MMP inhibitor.

Kashappa Goud H Desai1, Susan R Mallery, Steven P Schwendeman.   

Abstract

PURPOSE: The objective of this study was to develop poly(lactic-co-glycolic acid) (PLGA) injectable implants (i.e., millicylinders) with microencapsulated N-acetylcysteine (NAC) for site-specific controlled NAC release, for potential chemopreventive applications in persons with previously excised head and neck cancers.
METHODS: PLGA 50:50 (i.v.=0.57 dl/g) implants with 1-10 wt% NAC free acid or 10 wt% NAC salts (NAC-Na+, NAC-Mg2+ and NAC-Ca2+) were prepared by solvent extrusion and/or fluid energy micronization (FEM) methods. X-ray diffraction (XRD), scanning electron microscopy (SEM), and differential scanning calorimetry (DSC) studies were performed to evaluate the physical mixing of NAC with PLGA. PLGA implant degradation was studied by kinetics of polymer molecular weight decline (gel permeation chromatography) and mass loss. Release studies were conducted in N2 purged PBS (pH 7.4) at 37 degrees C in evacuated and sealed ampoules. NAC was quantified by HPLC at 210 nm.
RESULTS: XRD, SEM and DSC studies indicated that NAC had dissolved in the polymer phase at 1-3.5% w/w loading, but became discretely suspended in the polymer at 6-10% w/w. Initial burst and long-term release rate increased with increased drug loading, and release was uncharacteristically rapid at higher loading (6-10% w/w). The cause of the rapid release was linked to extensive plasticization, matrix porosity and general acid catalysis of PLGA degradation caused by the NAC free acid. PLGA millicylinders loaded with 10% w/w NAC-Ca2+ and NAC-Mg2+salts exhibited reduced burst (34 vs 13-22% release within a day of incubation for NAC free acid vs NAC-Ca2+ and NAC-Mg2+salts, respectively) and slow and continuous complete release over 4 weeks without significant NAC-catalyzed degradation of PLGA. Release of NAC from NAC-Ca2+/PLGA implant was slower than that of NAC-Mg2+/PLGA consistent with the lower solubility of the former salt. NAC with its free thiol was rapidly converted to its cystine dimer in the presence of molecular oxygen. PLGA released samples in sealed and evacuated ampoules indicated>80% parent NAC remaining after the 1 month release analysis irrespective of initial NAC free acid and salt forms.
CONCLUSION: By encapsulating the NAC-Mg2+ and NAC-Ca2+ salts in PLGA implants, the high initial burst, short release duration, and the general acid catalysis caused by the NAC free acid were each prevented and 1-month slow and continuous release was attained with minimal instability of the free thiol group.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17891553      PMCID: PMC2405913          DOI: 10.1007/s11095-007-9430-1

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  21 in total

Review 1.  Head and neck cancer: overview of recent developments and future directions.

Authors:  A A Forastiere
Journal:  Semin Oncol       Date:  2000-08       Impact factor: 4.929

2.  Measurement of hydrogen peroxide in biological samples containing high levels of ascorbic acid.

Authors:  G Bleau; C Giasson; I Brunette
Journal:  Anal Biochem       Date:  1998-10-01       Impact factor: 3.365

3.  Expression of matrix metalloproteinase 1, matrix metalloproteinase 2, and matrix metalloproteinase 9 in carcinoma of the head and neck.

Authors:  Alessandro Franchi; Marco Santucci; Emanuela Masini; Iacopo Sardi; Milena Paglierani; Oreste Gallo
Journal:  Cancer       Date:  2002-11-01       Impact factor: 6.860

Review 4.  Matrix metalloproteinases in tumour invasion and metastasis.

Authors:  S Curran; G I Murray
Journal:  J Pathol       Date:  1999-11       Impact factor: 7.996

5.  Effects of metal salts on poly(DL-lactide-co-glycolide) polymer hydrolysis.

Authors:  Y Zhang; S Zale; L Sawyer; H Bernstein
Journal:  J Biomed Mater Res       Date:  1997-03-15

6.  Controlled-release of doxorubicin from poly(lactide-co-glycolide) microspheres significantly enhances cytotoxicity against cultured AIDS-related Kaposi's sarcoma cells.

Authors:  S R Mallery; P Pei; J Kang; G M Ness; R Ortiz; J E Touhalisky; S P Schwendeman
Journal:  Anticancer Res       Date:  2000 Sep-Oct       Impact factor: 2.480

7.  Expression of MMPS, MT-MMP, and TIMPs in squamous cell carcinoma of the oral cavity: correlations with tumor invasion and metastasis.

Authors:  S Kurahara; M Shinohara; T Ikebe; S Nakamura; M Beppu; A Hiraki; H Takeuchi; K Shirasuna
Journal:  Head Neck       Date:  1999-10       Impact factor: 3.147

8.  Development of a multiple-drug delivery implant for intraocular management of proliferative vitreoretinopathy.

Authors:  T Zhou; H Lewis; R E Foster; S P Schwendeman
Journal:  J Control Release       Date:  1998-11-13       Impact factor: 9.776

9.  An eight-month clinical study of LA-2575 30.0 mg: a new 4-month, subcutaneous delivery system for leuprolide acetate in the treatment of prostate cancer.

Authors:  Oliver Sartor; Martin K Dineen; Ramon Perez-Marreno; Franklin M Chu; Graham J Carron; Robert C Tyler
Journal:  Urology       Date:  2003-08       Impact factor: 2.649

10.  Proteolysis in human breast and colorectal cancer.

Authors:  E A Garbett; M W Reed; N J Brown
Journal:  Br J Cancer       Date:  1999-09       Impact factor: 7.640

View more
  11 in total

1.  Controlled-release systemic delivery - a new concept in cancer chemoprevention.

Authors:  Ramesh C Gupta; Shyam S Bansal; Farrukh Aqil; Jeyaprakash Jeyabalan; Pengxiao Cao; Hina Kausar; Gilandra K Russell; Radha Munagala; Srivani Ravoori; Manicka V Vadhanam
Journal:  Carcinogenesis       Date:  2012-06-13       Impact factor: 4.944

2.  Mucoadhesive fenretinide patches for site-specific chemoprevention of oral cancer: enhancement of oral mucosal permeation of fenretinide by coincorporation of propylene glycol and menthol.

Authors:  Xiao Wu; Kashappa-Goud H Desai; Susan R Mallery; Andrew S Holpuch; Maynard P Phelps; Steven P Schwendeman
Journal:  Mol Pharm       Date:  2012-03-06       Impact factor: 4.939

Review 3.  Bioavailability of phytochemicals and its enhancement by drug delivery systems.

Authors:  Farrukh Aqil; Radha Munagala; Jeyaprakash Jeyabalan; Manicka V Vadhanam
Journal:  Cancer Lett       Date:  2013-02-19       Impact factor: 8.679

4.  Injectable SN-38-loaded Polymeric Depots for Cancer Chemotherapy of Glioblastoma Multiforme.

Authors:  Chawan Manaspon; Norased Nasongkla; Khuanjit Chaimongkolnukul; Pinunta Nittayacharn; Ketpat Vejjasilpa; Kanchana Kengkoom; Atthaporn Boongird; Suradej Hongeng
Journal:  Pharm Res       Date:  2016-08-05       Impact factor: 4.200

5.  Formulation and in vitro-in vivo evaluation of black raspberry extract-loaded PLGA/PLA injectable millicylindrical implants for sustained delivery of chemopreventive anthocyanins.

Authors:  Kashappa Goud H Desai; Karl F Olsen; Susan R Mallery; Gary D Stoner; Steven P Schwendeman
Journal:  Pharm Res       Date:  2010-02-11       Impact factor: 4.200

6.  A rapid method for creating drug implants: translating laboratory-based methods into a scalable manufacturing process.

Authors:  Cheng-Kuo Wang; Wan-Yi Wang; Robert F Meyer; Yuling Liang; Karen I Winey; Steven J Siegel
Journal:  J Biomed Mater Res B Appl Biomater       Date:  2010-05       Impact factor: 3.368

7.  Effect of formulation parameters on 2-methoxyestradiol release from injectable cylindrical poly(DL-lactide-co-glycolide) implants.

Authors:  Kashappa Goud H Desai; Susan R Mallery; Steven P Schwendeman
Journal:  Eur J Pharm Biopharm       Date:  2008-03-20       Impact factor: 5.571

8.  Effects of a topically applied bioadhesive berry gel on loss of heterozygosity indices in premalignant oral lesions.

Authors:  Brian S Shumway; Laura A Kresty; Peter E Larsen; Jared C Zwick; Bo Lu; Henry W Fields; Russell J Mumper; Gary D Stoner; Susan R Mallery
Journal:  Clin Cancer Res       Date:  2008-04-15       Impact factor: 12.531

9.  Optimizing therapeutic efficacy of chemopreventive agents: A critical review of delivery strategies in oral cancer chemoprevention clinical trials.

Authors:  Andrew S Holpuch; Kashappa-Goud H Desai; Steven P Schwendeman; Susan R Mallery
Journal:  J Carcinog       Date:  2011-09-21

10.  N-acetylcysteine-PLGA nano-conjugate: effects on cellular toxicity and uptake of gadopentate dimeglumine.

Authors:  Elham Poonaki; Mohammad Esfandyar; Hadi Hejazinia; Seyed Esmaeil Sadat Ebrahimi; Morteza Pirali Hamedani; Jafar Farzaneh; Mehdi Shafiee Ardestani
Journal:  IET Nanobiotechnol       Date:  2020-08       Impact factor: 1.847

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.